Why VTAMA?
Powerful skin clearance
In clinical studies, up to 46% of patients using VTAMA achieved clear or almost clear skin compared to 18% of patients using cream with no active ingredient in 8 weeks.*
Beneath the
surface
Tapinarof supports aryl hydrocarbon receptors (AhR), that play a role in how your skin functions.
Safe and well tolerated
VTAMA is safe to use on affected sensitive skin areas, and is safe for patients as young as 2 years old.
The most common side effects in patients with eczema treated with VTAMA were upper and lower respiratory tract infections, red raised bumps around the hair pores (folliculitis), headache, asthma, vomiting, ear infection, pain in extremity, and stomach-area (abdominal) pain.
*Patients also achieved a ≥2-grade improvement from baseline in Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD®) score in 8 weeks.
vIGA-AD is a registered trademark of Eli Lilly and Co.
VTAMA is recommended in the American Academy
of Dermatology (AAD) Guidelines:
VTAMA® (tapinarof) cream, 1% is strongly recommended by the AAD as a treatment option for patients ages 2 years and older with eczema (atopic dermatitis).†
Ask your doctor if VTAMA is right for you.
†In their 2026 Pediatric Guidelines and 2025 Adult Guidelines for the management of Atopic Dermatitis.